Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Dunn, Lauren K ^a   Mohammad, Khalid S ^a   Fournier, Pierrick G J ^a   McKenna, C Ryan ^a   Davis, Holly W ^a   Niewolna, Maria ^a   Peng, Xiang Hong ^a   Chirgwin, John M ^a   Guise, Theresa A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; MESSENGER RNA; PARATHYROID HORMONE; SD 208; SHORT HAIRPIN RNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; CXCR4 PROTEIN, HUMAN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CELL ACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL; ANIMAL; ANOXIA; BONE; BONE TUMOR; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANOXIA; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASM METASTASIS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70249108848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006896     Document Type: Article

References (72)

1. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
2. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
3. Massague J (2008) TGFbeta in Cancer. Cell 134: 215-230.
4. Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19: 2783-2810.
5. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359: 2814-2823.
6. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206.
7. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, et al. (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277: 24571-24578.
8. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
9. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, et al. (2005) Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65: 11001-11009.
10. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, et al. (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62: 5571-5579.
11. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, et al. (2006) The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202-2209.
12. Kang Y, He W, Tulley S, Gupta GP, Serganova I, et al. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 102: 13909-13914.
13. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, et al. (2007) Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis. Cancer Res 67: 2317-2324.
14. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, et al. (2006) Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 12: 4315-4330.
15. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, et al. (2006) Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66: 6714-6721.
16. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, et al. (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109: 1607-1615.
17. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, et al. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109: 1551-1559.
18. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, et al. (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10: 7540-7546.
19. Hirao M, Hashimoto J, Yamasaki N, Ando W, Tsuboi H, et al. (2007) Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab 25: 266-276.
20. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
21. Brown JM, Wilson RW (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
22. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
23. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
24. Duivenvoorden WC, Hirte HW, Singh G (1999) Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 17: 27-34.
25. Iida J, McCarthy JB (2007) Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. Melanoma Res 17: 205-213.
26. Ao M, Franco OE, Park D, Raman D, Williams K, et al. (2007) Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244-4253.
27. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, et al. (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7: 1472-1482.
28. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, et al. (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14: 1096-1104.
29. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, et al. (2008) NVPAUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850-2860.
30. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, et al. (2007) Ki26894, a novel transforming growth factor-β; type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Science 98: 127-133.
31. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, et al. (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961.
32. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375.
33. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, et al. (2004) 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10: 8665-8673.
34. Zhou D, Matchett GA, Jadhav V, Dach N, Zhang JH (2008) The effect of 2-methoxyestradiol, a HIF-1 alpha inhibitor, in global cerebral ischemia in rats. Neurol Res 30: 268-271.
35. Raleigh JA, Calkins-Adams DP, Rinker LH, Ballenger CA, Weissler MC, et al. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58: 3765-3768.
36. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, et al. (1998) Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71: 270-277.
37. Janssen HL, Haustermans KM, Sprong D, Blommestijn G, Hofland I, et al. (2002) HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54: 1537-1549.
38. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, et al. (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490.
39. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM (1998) Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58: 4008-4014.
40. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, et al. (1998) Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 426: 271-278.
41. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, et al. (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481.
42. Cicek M, Iwaniec UT, Goblirsch MJ, Vrabel A, Ruan M, et al. (2007) 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res 67: 10106-10111.
43. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, et al. (2009) Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 15: 1460-1465.
44. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98: 1736-1740.
45. Lipton A (2008) Emerging role of bisphosphonates in the clinic - antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34 Suppl 1: S25-30.
46. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67: 4157-4163.
47. Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, et al. (2007) Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol 81: 557-566.
48. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, et al. (2001) Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276: 38527-38535.
49. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67: 563-572.
50. Wang J, Loberg R, Taichman RS (2006) The pivotal role of CXCL12 (SDF-1)/ CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25: 573-587.
51. Pulaski BA, Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumor model. Curr Protoc Immunol;Chapter 20: Unit 20 22.
52. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, et al. (2009) Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol.
53. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, et al. (2009) Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21: 761-767.
54. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, et al. (2003) T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 550: 79-83.
55. Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, et al. (2009) Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss. J Bone Miner Res.
56. Bauerle T, Bartling S, Berger M, Schmitt-Graff A, Hilbig H, et al. (2008) Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol.
57. Bauerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, et al. (2008) Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 10: 511-520.
58. Mooberry SL (2003) Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 6: 355-361.
59. Mooberry SL (2003) New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15: 425-430.
60. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, et al. (2009) Pharmacologic inhibition of the tgf-Beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 4: e5275.
61. Wang Y, Wan C, Deng L, Liu X, Cao X, et al. (2007) The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117: 1616-1626.
62. Komatsu DE, Bosch-Marce M, Semenza GL, Hadjiargyrou M (2007) Enhanced bone regeneration associated with decreased apoptosis in mice with partial HIF-1alpha deficiency. J Bone Miner Res 22: 366-374.
63. Arnett TR, Gibbons DC, Utting JC, Orriss IR, Hoebertz A, et al. (2003) Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol 196: 2-8.
64. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, et al. (2008) Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 454: 221-225.
65. Knowles HJ, Athanasou NA (2008) Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 215: 56-66.
66. Knowles HJ, Athanasou NA (2009) Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J Pathol.
67. Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11: 1121-1131.
68. Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, et al. (2003) Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144: 785-792.
69. Zhang Q, Guo R, Lu Y, Zhao L, Zhou Q, et al. (2008) VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem 283: 13491-13499.
70. Bartholin L, Wessner LL, Chirgwin JM, Guise TA (2007) The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett 246: 230-236.
71. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a Causal Role of Parathyroid Hormone-related Protein in the Pathogenesis of Human Breast Cancer-mediated Osteolysis. J Clin Invest 98: 1544-1549.
72. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, et al. (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 100: 10954-10959.